Credit Suisse’s Mirum Pharmaceuticals MIRM Stock Holding History

Credit Suisse’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$633K	Buy	25,207 +1,129	+5%	+$31K	﹤0.01%	2529
2023 Q4	$711K	Buy	24,078 +1,601	+7%	+$48.5K	﹤0.01%	2553
2023 Q3	$710K	Sell	22,477 -6,538	-23%	-$179K	﹤0.01%	2493
2023 Q2	$751K	Buy	29,015 +12,489	+76%	+$332K	﹤0.01%	2571
2023 Q1	$397K	Buy	16,526 +4,495	+37%	+$102K	﹤0.01%	2872
2022 Q4	$235K	Sell	12,031 -144	-1%	-$2.85K	﹤0.01%	3131
2022 Q3	$255K	Buy	12,175 +1,692	+16%	+$40.7K	﹤0.01%	3149
2022 Q2	$204K	Buy	+10,483	New	+$247K	﹤0.01%	3315

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse's MIRM Position: Q1 2024 in Review

Credit Suisse increased its Mirum Pharmaceuticals (MIRM) stake by 4.7% in Q1 2024, buying an estimated $31K and bringing the position to 25,207 shares worth $633K. The position accounts for ﹤0.01% of the portfolio, ranked #2529.

Credit Suisse first reported a position in MIRM in Q2 2022 and has held it in 8 quarters since. The position peaked at $751K in Q2 2023. 172 funds tracked by Wall St. Rank hold MIRM as of Q1 2024.

Credit Suisse held 25,207 shares of Mirum Pharmaceuticals worth $633K as of Q1 2024.
Credit Suisse bought 1,129 Mirum Pharmaceuticals shares in Q1 2024, an estimated $31K.
Mirum Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2529 holding.
Credit Suisse first reported a position in Mirum Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
Credit Suisse's Mirum Pharmaceuticals position peaked at $751K in Q2 2023.
172 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.